Chimerix, Inc. - Common Stock (CMRX)

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

BALA CYNWYD, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQCMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholders.

-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-

DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 270,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).

Potential First Approval for Patients with Recurrent H3 K27M-mutant Diffuse Glioma

DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET.

DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to six new employees of non-statutory stock options to purchase up to a total of 355,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).

Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development

Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility

Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma

DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 385,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).

DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming presentations at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting, which will be held in Houston, TX from November 21 – 24, 2024.

– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 –

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview.

DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment in accordance with Nasdaq Listing rule 5635(c)(4).

DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will present a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.

DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment in accordance with Nasdaq Listing rule 5635(c)(4).

     – Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 –

EQNX::TICKER_START (NYSENNVC),NASDAQ:BCRXNASDAQBCRX)(NASDAQ:VERUNASDAQVERU,(NASDAQ:CMRXNASDAQ),(NASDAQ:SIGASIGA) EQNX::TICKER_END

PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - The demand for antiviral drugs has been increasing globally due to the growing prevalence of viral diseases. Customers are increasingly seeking antiviral drugs that are effective against a wide range of viruses and have minimal side effects. They also prefer drugs that are easy to administer and have a shorter treatment duration. The Antiviral Drugs segment is expected to experience significant growth, which is mainly driven by the testing of novel treatments for COVID-19. There are also more general drivers of the market: the rising number of HIV cases worldwide and the need for continuous development in the field of antiviral drugs. A report from Statista said that: “The projected revenue in the Antiviral Drugs market worldwide is estimated to reach US$51.18bn in 2024. It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.58%, leading to a market volume of US$55.36bn by 2029. In terms of global comparison, United States is anticipated to generate the highest revenue, with US$30,640.00m in 2024. In the worldwide market for antiviral drugs, the United States leads in research and development, driving innovation and setting industry standards.” Active Biotechs in the biotech markets today include: NanoViricides, Inc. (NYSENNVC), BioCryst Pharmaceuticals, Inc. NASDAQ: BCRXNASDAQBCRX)(NASDAQ: VERUNASDAQVERU, Chimerix (NASDAQ: CMRXNASDAQ), SIGA Technologies, Inc. (NASDAQ: SIGASIGA).

DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 13, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business overview.

DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQCMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.

– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 –